Search results
Results from the WOW.Com Content Network
An alpha privative or, rarely, [1] privative a (from Latin alpha prīvātīvum, from Ancient Greek α στερητικόν) is the prefix a-or an-(before vowels) that is used in Indo-European languages such as Sanskrit and Greek and in words borrowed therefrom to express negation or absence, for example the English words of Greek origin atypical, anesthetic, and analgesic.
Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. [1] It has the potential to provide highly targeted treatment, especially to microscopic tumour cells.
Patients and their diseases are profiled in order to identify the most effective treatment for their specific case. Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment ( pharmacotherapy ) for cancer , [ 1 ] others being hormonal therapy and cytotoxic chemotherapy .
a-, called alpha privative, from Ancient Greek ἀ-, ἀν-, from Proto-Hellenic *ə-; e.g. apathetic, abiogenesis. These all stem from a PIE syllabic nasal privative *n̥-, the zero ablaut grade of the negation *ne, i.e. "n" used as a vowel, as in some English pronunciations of "button". This is the source of the 'n' in 'an-' privative ...
not, without (alpha privative) Greek analgesia: ana-back, again, up Greek ἀνα-(ana-) anaplasia: an-anus: Latin anal andr-pertaining to a man: Greek ἀνήρ, ἀνδρ-(anḗr, andr-), male android, andrology, androgen: angi-blood vessel: Greek ἀγγεῖον (angeîon) angiogram, angioplasty: aniso-describing something as unequal
For these patients PUVA bath therapy may be a good option. Long term use of PUVA therapy with a pill has been associated with higher rates of skin cancer. [7] The most significant complication of PUVA therapy for psoriasis is squamous cell skin cancer. Two carcinogenic components of the therapy include the nonionizing radiation of UVA light as ...
Very common adverse effects include nausea and headache (may affect more than 10% of people). Common adverse effects include injection site reactions, back pain, upper respiratory tract infections, melanocyte naevus, decreased appetite, migraine, dizziness, weakness, fatigue, lethargy, sleepiness, hot flashes, abdominal pain, diarrhea, vomiting, flushing, development of warts, spots, and ...
Eftilagimod alpha (INN; [1] development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3 .